FDAnews Drug Daily Bulletin

CUBIST PHARMACEUTICALS 'OUTPERFORM,' TARGET PRICE RAISED

June 1, 2006
A A

Analysts at RBC Capital Markets reiterate their "outperform" rating on Cubist Pharmaceuticals. The target price has been raised from $25 to $33.
Newratings